Inactive Instrument

ChemoCentryx, Inc.

CCXI

US16383L1061

ChemoCentryx to Participate in Two Upcoming Investor Conferences

November 10, 2021 at 08:00 am EST

SAN CARLOS, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences:

Stifel 2021 Virtual Healthcare Conference
Fireside Chat Wednesday, November 17 at 2:00 p.m. Eastern Time

Piper Sandler 33rd Annual Virtual Healthcare Conference
On-demand presentation available beginning Monday, November 22 at 10:00 a.m. Eastern Time

A live audio webcast of the Stifel fireside chat, as well as the on-demand Piper Sandler presentation can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. Replays of both the Stifel and Piper Sandler presentations will be available on the Company's website for two weeks following the respective presentation dates.

About ChemoCentryx
ChemoCentryx is a biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. In the United States, ChemoCentryx markets TAVNEOS™ (avacopan), the first approved orally-administered inhibitor of the complement 5a receptor as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis. TAVNEOS is also in late-stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G). Additionally, ChemoCentryx has early-stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer. For more information visit www.chemocentryx.com

Contacts:

Susan M. Kanaya
Executive Vice President,
Chief Financial and Administrative Officer
investor@chemocentryx.com

Media:
Stephanie Tomei
408.234.1279
media@chemocentryx.com

Investors:
Lee Roth, Burns McClellan
212.213.0006
lroth@burnsmc.com

Source: ChemoCentryx, Inc.

2021 GlobeNewswire, Inc., source Press Releases

Latest news about ChemoCentryx, Inc.

ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from S&P Global BMI Index	22-10-24	CI
ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from S&P TMI Index	22-10-24	CI
ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from S&P Biotechnology Select Industry Index	22-10-24	CI
Amgen Completes ChemoCentryx Acquisition	22-10-20	MT
Chemocentryx, Inc. Announces Executive Changes	22-10-20	CI
ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from NASDAQ Composite Index	22-10-20	CI
Amgen Inc. completed the acquisition of ChemoCentryx, Inc. from a group of shareholders.	22-10-19	CI
ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from NASDAQ Biotechnology Index	22-10-19	CI
Swissmedic OKs ChemoCentryx's Combo Therapy For Rare Blood Vessel Disease	22-09-27	MT
Insider Sell: Chemocentryx	22-08-18	MT
UK Agency Recommends Tavneos Combo for Treatment of Rare Blood Vessel Disease	22-08-18	MT
Biotech stocks pin bounce back hopes on M&A boost	22-08-12	RE
Stifel Cuts ChemoCentryx to Hold From Buy, Price Target to $52 From $86	22-08-10	MT
Insider Sell: ChemoCentryx	22-08-09	MT
Insider Sell: ChemoCentryx	22-08-09	MT
ChemoCentryx, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-08	CI
SVB Securities Downgrades ChemoCentryx to Market Perform From Outperform, Adjusts Price Target to $52 From $64	22-08-05	MT
HC Wainwright Downgrades ChemoCentryx to Neutral From Buy, Adjusts Price Target to $52 From $101	22-08-05	MT
Amgen Signals Additional $100 Million Hit to Revenue From Foreign Exchange Following Volume-Driven Second-Quarter Beat	22-08-05	MT
MarketScreener’s World Press Review : August 5, 2022	22-08-05
Canaccord Genuity Downgrades ChemoCentryx to Hold From Buy; Price Target is $52	22-08-05	MT
Healthcare Shares Slip Amid Deal News -- Healthcare Roundup	22-08-04	DJ
Amgen 2Q Profit Jumped After Write-Off From 2021 Acquisition	22-08-04	DJ
Sector Update: Health Care Stocks Slipping Ahead of Thursday Close	22-08-04	MT
Sector Update: Health Care	22-08-04	MT

Chart ChemoCentryx, Inc.

Duration

Period

More charts

Company Profile

ChemoCentryx, Inc. is an integrated biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. The Company is targeting the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. Its development pipelines include TAVNEOS and Immuno-Oncology. TAVNEOS is for the treatment of severe hidradenitis suppurativa (HS) and seeks to advance TAVNEOS into Phase III clinical development for the treatment of severe HS. The Company's CCX559 is orally-administered investigational inhibitor for programmed death protein 1/programmed death-ligand 1 (PD-1/PD-L1), which is developing for the treatment of various cancers. It markets TAVNEOS (avacopan) as an adjunctive treatment for adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis associated vasculitis, specifically granulomatosis with polyangiitis and microscopic polyangiitis.

Sector

Pharmaceuticals

More about the company

Sector Biopharmaceuticals

	1st Jan change	Capi.
CSL LIMITED	-2.86%	87.31B
SAMSUNG BIOLOGICS CO.,LTD.	+3.95%	40.86B
BIOGEN INC.	-21.94%	29.36B
UCB	+53.74%	24.49B
BIOMARIN PHARMACEUTICAL INC.	-5.41%	17.31B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-44.23%	11.26B
INCYTE CORPORATION	-17.60%	11.62B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-13.96%	11.31B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.31B

Biopharmaceuticals